glp 1 parkinson's disease A New Treatment Strategy for through the Gut–Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway GLP-1R Agonists - Glucagon-Like Peptide

Carnitine is a friend in HFpEF and foe in HFrEF

Dual-layer ampoule and cream formula delivers lasting moisture

Upgrade Labs 5th Street is owned and operated by Drs

BPC-157 , , , , -

Timeline of Regulatory Milestones 2005: Exenatide (Byetta): First GLP-1 agonist approved, twice-daily injections 2010: Liraglutide (Victoza): Longer-lasting, once-daily injection 2014: Dulaglutide (Trulicity): Once-weekly injection arrives 2017: Semaglutide (Ozempic): First once-weekly injection for diabetes with powerful weight-loss effects 2019: Oral semaglutide (Rybelsus): First GLP-1 pill makes it past the stomachs defenses 2021: High-dose semaglutide (Wegovy): FDA approval for obesity treatment 2022: Tirzepatide (Mounjaro): First dual GLP-1/GIP agonist for diabetes 2023: Tirzepatide (Zepbound): Expanded approval for obesity 20232024 : Widespread shortages: Skyrocketing demand for GLP-1s leads to limited availability The shortage that began in late-2023, driven by soaring off-label demand and supply-chain bottlenecks left millions of patients unable to fill even maintenance scripts